GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System
Combining a durable, proven stent graft with a delivery system that offers controlled, staged deployment for the endovascular repair of aneurysms, transections and Type B dissections of the thoracic aorta.
The new delivery system allows accurate device positioning and location refinement during the intermediate stage before full deployment, and continuous blood flow throughout the procedure.
Oversizing matters
Featured resources
IDE 5 year data brochure
Newly published 5 year data for aneurysm, dissection and transection clinical trials
PDF, 17.58 MB
* Migrations are reported as those requiring reintervention.
1. W. L. Gore & Associates. Evaluation of the GORE Conformable TAG® Thoracic Endoprosthesis for Treatment of Acute Complicated Type B Aortic Dissection. NLM Identifier: NCT00908388. Published May 25, 2009. Updated October 27, 2017. Accessed June 7, 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT00908388
2. W. L. Gore & Associates. Evaluation of the GORE Conformable TAG® for Treatment of Traumatic Transection. NLM Identifier: NCT00917852. Published June 10, 2009. Updated August 25, 2017. Accessed June 7, 2022. https://clinicaltrials.gov/ct2/show/NCT00917852
3. W. L. Gore & Associates. An Evaluation of the GORE Conformable TAG® Thoracic Endoprosthesis for the Primary Treatment of Aneurysm of the Descending Thoracic Aortic. NLM Identifier: NCT00874250. Published April 2, 2009. Updated August 25, 2017. Accessed June 7, 2022. https://clinicaltrials.gov/ct2/show/NCT00874250
INDICATIONS FOR USE IN THE U.S. The GORE® TAG® Conformable Thoracic Stent Graft is intended for endovascular repair of all lesions of the descending thoracic aorta, including: Isolated lesions in patients who have appropriate anatomy, including: Adequate iliac/femoral access, aortic inner diameter in the range of 16-42 mm, ≥ 20 mm non-aneurysmal aorta proximal and distal to the lesion; Type B dissections in patients who have appropriate anatomy, including: Adequate iliac/femoral access, ≥ 20 mm landing zone proximal to the primary entry tear; proximal extent of the landing zone must not be dissected, diameter at proximal extent of proximal landing zone in the range of 16-42 mm.
CONTRAINDICATIONS: Patients with known sensitivities or allergies to the device materials; patients who have a condition that threatens to infect the graft. Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. RXOnly
22760250-EN
